Lacrimal Sac Tumors--A Review.

Krishna, Y and Coupland, SE ORCID: 0000-0002-1464-2069
(2017) Lacrimal Sac Tumors--A Review. Asia-Pacific journal of ophthalmology (Philadelphia, Pa.), 6 (2). pp. 173-178.

[img] Text
Title page LS tumours_APJO_final.docx - Author Accepted Manuscript

Download (26kB)
[img] Text
revised and final manuscript LS tumours_APJO_100317.docx - Author Accepted Manuscript

Download (54kB)
[img] Image
Fig1.jpg - Author Accepted Manuscript

Download (89kB)
[img] Image
Fig2.jpg - Author Accepted Manuscript

Download (76kB)
[img] Image
Fig3.jpg - Author Accepted Manuscript

Download (123kB)


Tumors of the lacrimal sac are rare but their recognition and early management are imperative, as they are locally invasive and potentially life-threatening. Because of their rarity, large clinical studies with statistically significant data on the natural course, management, and prognosis of these neoplasms are unavailable. Current practices are therefore based on a few case series and a small number of isolated case reports. Most tumors are primary and of epithelial origin (60-94%), of which 55% are malignant. Lacrimal sac tumors typically present with epiphora and a palpable mass over the medial canthus and are thus often erroneously diagnosed as chronic dacryocystitis. A full history with clinical and diagnostic workup is essential to plan treatment, which is often multi-disciplinary. Statistically significant associations have been shown with higher tumor staging and size with increased metastatic risk and lower survival rates. Management usually involves complete surgical resection with adjuvant radiotherapy and/or chemotherapy for malignant lesions. Long-term follow-up is required, as recurrences and metastases can occur many years after initial treatment.

Item Type: Article
Uncontrolled Keywords: lacrimal sac tumors, secondary nasolacrimal obstruction, dacryocystitis
Depositing User: Symplectic Admin
Date Deposited: 09 Jun 2017 09:58
Last Modified: 19 Jan 2023 07:03
DOI: 10.22608/apo.201713
Related URLs: